Delayed
Japan Exchange
10:26:55 2024-07-15 pm EDT
|
5-day change
|
1st Jan Change
|
183
JPY
|
0.00%
|
|
+7.02%
|
+10.91%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
101,628
|
70,754
|
16,537
|
12,300
|
16,494
|
-
|
-
|
Enterprise Value (EV)
1 |
101,628
|
67,584
|
16,436
|
9,986
|
16,494
|
16,494
|
16,494
|
P/E ratio
|
-18.3
x
|
-13.7
x
|
-2.96
x
|
-2.93
x
|
-4.59
x
|
-5.5
x
|
-5.41
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3,764
x
|
1,726
x
|
184
x
|
102
x
|
55
x
|
11.8
x
|
7.16
x
|
EV / Revenue
|
3,764
x
|
1,726
x
|
184
x
|
102
x
|
55
x
|
11.8
x
|
7.16
x
|
EV / EBITDA
|
-
|
-
|
-3.45
x
|
-3.43
x
|
-22.9
x
|
-22.9
x
|
-
|
EV / FCF
|
-23.6
x
|
-
|
-
|
-4.32
x
|
-2.82
x
|
-10.8
x
|
-6.01
x
|
FCF Yield
|
-4.24%
|
-
|
-
|
-23.2%
|
-35.5%
|
-9.26%
|
-16.6%
|
Price to Book
|
13
x
|
8.19
x
|
3.87
x
|
3.19
x
|
4.84
x
|
39.8
x
|
-9.84
x
|
Nbr of stocks (in thousands)
|
51,666
|
55,148
|
61,704
|
74,543
|
90,130
|
-
|
-
|
Reference price
2 |
1,967
|
1,283
|
268.0
|
165.0
|
183.0
|
183.0
|
183.0
|
Announcement Date
|
2/12/21
|
2/14/22
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
27
|
41
|
90
|
121
|
300
|
1,392
|
2,304
|
EBITDA
1 |
-
|
-
|
-4,793
|
-3,589
|
-719
|
-719
|
-
|
EBIT
1 |
-4,183
|
-5,384
|
-5,179
|
-3,379
|
-2,889
|
-2,633
|
-2,580
|
Operating Margin
|
-15,492.59%
|
-13,131.71%
|
-5,754.44%
|
-2,792.56%
|
-963%
|
-189.08%
|
-111.95%
|
Earnings before Tax (EBT)
1 |
-5,378
|
-4,462
|
-5,330
|
-3,626
|
-3,289
|
-2,756
|
-3,097
|
Net income
1 |
-5,512
|
-4,910
|
-5,169
|
-3,823
|
-3,289
|
-2,761
|
-2,708
|
Net margin
|
-20,414.81%
|
-11,975.61%
|
-5,743.33%
|
-3,159.5%
|
-1,096.33%
|
-198.28%
|
-117.51%
|
EPS
2 |
-107.2
|
-93.36
|
-90.67
|
-56.22
|
-39.90
|
-33.29
|
-33.80
|
Free Cash Flow
1 |
-4,307
|
-
|
-
|
-2,850
|
-5,853
|
-1,528
|
-2,745
|
FCF margin
|
-15,951.85%
|
-
|
-
|
-2,355.37%
|
-1,951%
|
-109.73%
|
-119.11%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/12/21
|
2/14/22
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
---|
Net sales
1 |
14
|
20
|
11
|
11
|
22
|
8
|
60
|
7
|
101
|
108
|
6
|
-
|
10
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1,849
|
-2,443
|
-1,429
|
-1,635
|
-3,064
|
-1,041
|
-1,074
|
-888
|
-667
|
-1,555
|
-743
|
-1,081
|
-1,049
|
Operating Margin
|
-13,207.14%
|
-12,215%
|
-12,990.91%
|
-14,863.64%
|
-13,927.27%
|
-13,012.5%
|
-1,790%
|
-12,685.71%
|
-660.4%
|
-1,439.81%
|
-12,383.33%
|
-
|
-10,490%
|
Earnings before Tax (EBT)
1 |
-2,624
|
-1,807
|
-1,415
|
-
|
-3,213
|
-1,056
|
-
|
-735
|
-
|
-1,321
|
-709
|
-
|
-2,511
|
Net income
1 |
-2,608
|
-1,892
|
-1,460
|
-
|
-3,260
|
-696
|
-
|
-732
|
-
|
-1,392
|
-700
|
-
|
-2,424
|
Net margin
|
-18,628.57%
|
-9,460%
|
-13,272.73%
|
-
|
-14,818.18%
|
-8,700%
|
-
|
-10,457.14%
|
-
|
-1,288.89%
|
-11,666.67%
|
-
|
-24,240%
|
EPS
2 |
-50.82
|
-36.60
|
-26.48
|
-32.63
|
-59.11
|
-12.02
|
-19.54
|
-11.51
|
-10.37
|
-21.88
|
-9.910
|
-24.43
|
-29.05
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/6/20
|
8/10/21
|
5/10/22
|
8/9/22
|
8/9/22
|
11/14/22
|
2/14/23
|
5/12/23
|
8/14/23
|
8/14/23
|
11/14/23
|
2/14/24
|
5/13/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
3,170
|
101
|
2,314
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-4,307
|
-
|
-
|
-2,850
|
-5,853
|
-1,528
|
-2,745
|
ROE (net income / shareholders' equity)
|
-54.6%
|
-59.6%
|
-79.4%
|
-92.8%
|
-123%
|
-170%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-18.9%
|
-27.3%
|
-24%
|
-23%
|
-
|
-
|
Assets
1 |
-
|
25,938
|
18,913
|
15,914
|
14,300
|
-
|
-
|
Book Value Per Share
2 |
152.0
|
157.0
|
69.30
|
51.70
|
37.80
|
4.600
|
-18.60
|
Cash Flow per Share
2 |
-103.0
|
-88.40
|
-83.90
|
-52.90
|
-35.30
|
-31.60
|
-21.30
|
Capex
1 |
362
|
245
|
250
|
28
|
400
|
400
|
400
|
Capex / Sales
|
1,340.74%
|
597.56%
|
277.78%
|
23.14%
|
133.33%
|
28.73%
|
17.36%
|
Announcement Date
|
2/12/21
|
2/14/22
|
2/14/23
|
2/14/24
|
-
|
-
|
-
|
Average target price
280
JPY Spread / Average Target +53.01% Consensus |
1st Jan change
|
Capi.
|
---|
| +10.91% | 104M | | +20.63% | 126B | | +24.16% | 27.95B | | -20.17% | 20.5B | | -16.06% | 17.12B | | -18.07% | 16.1B | | -47.70% | 14.97B | | +11.92% | 14.84B | | +58.32% | 14.38B | | +149.98% | 12.37B |
Bio Therapeutic Drugs
|